Physician profile
Nalin Mathur
NPI 1891791935
$3,468.04
in general payments reported to CMS, 2019-2025
24 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $277 · 2021: $750 · 2022: $526 · 2023: $484 · 2024: $690 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.08 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $432.81 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $398.16 | 2019-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $388.79 | 2021-2025 | |
| Glaxosmithkline, LLC. | $369.81 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $366.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.54 | 2020-2022 | |
| Novo Nordisk INC | $288.27 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $216.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $163.31 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $149.06 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $61.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $60.20 | 2021-2023 | Xarelto |
| Corcept Therapeutics | $47.35 | 2025 | Korlym |
| Regeneron Healthcare Solutions, INC. | $37.39 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.11 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.57 | 2019 | |
| Exact Sciences Corporation | $21.92 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $21.83 | 2019 | |
| Allergan, INC. | $19.83 | 2020 | |
| Astellas Pharma US INC | $15.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2019 | |
| Medtronic, INC. | $14.45 | 2023 | Intellis Adaptivestim |
| Medtronic USA, INC. | $12.22 | 2019 | |
| Merck Sharp & Dohme LLC | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalin Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.